Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 11/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.73 |
| ▸ | FYN | P06241 | 7/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.55 |
| ▸ | KIT | P10721 | 2/20 | 0.55 |
| ▸ | FLT3 | P36888 | 2/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL834829 | 0.90 | FGFR1 (0.70) | FGFR3FGFR1FYNNTRK1PDGFRB | |
| SCHEMBL837206 | 0.90 | FGFR3 (0.70) | FGFR3FGFR1FYNNTRK1PDGFRB | |
| SCHEMBL837301 | 0.87 | FGFR3 (0.67) | FGFR3FGFR1FYNNTRK1PDGFRB | |
| SCHEMBL835499 | 0.86 | FGFR3 (0.66) | FGFR3FGFR1FYNNTRK1PDGFRB | |
| SCHEMBL2340954 | 0.86 | FGFR3 (0.66) | FGFR3FGFR1FYNNTRK1PDGFRB | |
| SCHEMBL836186 | 0.86 | FGFR1 (0.65) | FGFR3FGFR1FYNNTRK1PDGFRB | |
| SCHEMBL836782 | 0.86 | FGFR1 (0.65) | FGFR3FGFR1FYNNTRK1PDGFRB | |
| SCHEMBL2347266 | 0.85 | FGFR1 (0.64) | FGFR3FGFR1FYNNTRK1PDGFRB | |
| SCHEMBL836898 | 0.83 | FGFR3 (0.67) | FGFR3FGFR1FYNNTRK1PDGFRB | |
| SCHEMBL12448288 | 0.81 | FGFR1 (0.66) | FGFR3FGFR1FYNNTRK1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | claimed |
| EP-2183027-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-08-31 | — | — | EP | claimed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | claimed |
| EP-2183027-A1 | ORGANIC COMPOUNDS | Novartis Ag (CH) | 2010-05-12 | — | — | EP | claimed |
| WO-2009013335-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | claimed |
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| EP-2183027-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| EP-2183027-A1 | ORGANIC COMPOUNDS | Novartis Ag (CH) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009013335-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204235-A1 | ORGANIC COMPOUNDS | ALK, OR10J3, FFAR4 | FGFR3 81/4885FGFR1 20/4885FYN 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.